CAIRO - 31 January 2022: A first batch of 15,000 doses of Evusheld (tixagevimab co-packaged with cilgavimab), AstraZeneca’s long-acting antibody combination which provides pre-exposure protection from COVID-19, arrived at Cairo international airport on Saturday (29 January). Egypt is the first African country and the fourth globally to receive Evusheld. The doses arrived within days of obtaining Emergency Use Authorization from the Egyptian Drug Authority (EDA), and further deliveries are expected in the coming weeks as part of a total supply of 50,000 doses in 2022. The collaboration between the Ministry of Health and Population and AstraZeneca played a key role in our efforts to respond to the pandemic through the provision of the AstraZeneca COVID-19 vaccine. With Evusheld, we now have better capabilities to protect immunocompromised patients in Egypt.”Hatem Werdany, Country President for Egypt, AstraZeneca said: “We are delighted to see the first doses of Evusheld arrive in Egypt, soon after being granted Emergency Use Authorization by the Egyptian Drug Authority.
